(2023) on a large, multi-center cohort validated a refined panel of biomarkers, including CYFRA21-1 and CEA, for the early detection of lung cancer, further cementing the role of such panels in clinical decision-making. This evidence concerns the gene CEACAM5 and lung carcinoma.